Memorial Sloan Kettering Cancer Center has created an internal infrastructure that most academic research institutions lack: a dedicated office designed to move cancer discoveries from the lab directly into patient treatments. The Office of Entrepreneurship and Commercialization (OEC) manages a comprehensive network of programs that support drug discovery, digital health innovation, and technology development across the institution, addressing a critical gap in how academic research typically gets commercialized.

Why Do Most Academic Researchers Struggle to Commercialize Their Discoveries?

The path from laboratory discovery to a treatment that reaches patients is notoriously complex and expensive. Most academic researchers face a difficult choice: either abandon promising projects due to lack of resources, or spend years navigating the business, regulatory, and funding challenges of development on their own. This reality forces many institutions to "triage or abandon" projects that could have real potential, according to MSK's approach to the problem.

MSK's response has been to build what industry experts recognize as a rare institutional advantage. The center was recently ranked fourth among 60 biomedical institutes in the 2026 Cure Innovation Index, with recognition for its "strength across both discovery science and the processes that move findings toward clinical application." In 2025, MSK was also named to Fast Company's "100 Best Workplaces for Innovators," reflecting the institution's commitment to supporting entrepreneurship at scale.

What Programs Does MSK Use to Bridge the Gap Between Discovery and Patients?

The OEC operates through a coordinated set of specialized programs, each designed to address different stages of innovation development. Rather than forcing researchers to choose between their science and business development, MSK provides integrated support that keeps projects moving forward.

• Product Development and Therapeutics Bridge Labs: These in-house initiatives provide strategic infrastructure, scientific expertise, regulatory guidance, and multifaceted resources necessary to advance therapeutic innovations from early-stage discovery through clinical development.
• Technology Development Investment Fund: This program offers gap-funding investment vehicles specifically designed for projects with strong commercialization potential, helping researchers de-risk their work before seeking external partnerships.
• Entrepreneurship Initiative: MSK's startup incubator supports researchers who want to launch their own companies based on institutional innovations, providing both mentorship and business development resources.
• Life Sciences Therapeutics Accelerator and Innovation Hub: These business accelerator programs create collaboration opportunities between MSK researchers and life sciences and digital health companies, facilitating partnerships that can scale innovations rapidly.

The results speak to the effectiveness of this model. In recent years, MSK has generated 66 invention disclosures, filed 99 patent applications, and secured 29 patents issued. These numbers reflect not just intellectual property creation, but a systematic approach to protecting and commercializing innovations that could benefit cancer patients worldwide.

How to Advance Cancer Research Innovations From Lab to Patient Care

• Establish dedicated commercialization infrastructure: Create internal teams with expertise in technology development, business strategy, regulatory affairs, and intellectual property management so researchers don't have to navigate these challenges alone.
• Provide staged funding mechanisms: Offer gap-funding programs that support projects at critical early stages, reducing the financial risk that causes promising innovations to be abandoned before they can attract external investment.
• Build industry partnership networks: Develop formal channels connecting academic researchers with pharmaceutical companies, biotech firms, and digital health entrepreneurs, enabling faster translation of discoveries into commercial products.
• Support multiple pathways to impact: Allow researchers to choose between licensing their work to established companies, launching startups, or collaborating with industry partners, recognizing that different innovations require different commercialization strategies.

Leadership of the OEC falls to Yashodhara Dash, who was appointed Vice President of the Office in October 2024. Dash brings a background in immunology and business development, having joined MSK in 2007 and held a series of management roles within the commercialization function. Under her direction, the Office actively supports the entire lifecycle of drug development at MSK, from initial laboratory discoveries through startup formation or licensing to pharmaceutical and biotech companies.

"OEC's mission is to ensure that MSK innovation is developed and applied for the common good," the institution stated in describing its approach.

Office of Entrepreneurship and Commercialization, Memorial Sloan Kettering Cancer Center

The OEC is staffed by an expert team of technology development professionals who bring rigorous scientific, healthcare, and business backgrounds to the challenges of developing, managing, protecting, and commercializing MSK innovation. This multidisciplinary approach addresses a fundamental problem in academic research: most scientists are trained in their discipline, not in business development or regulatory strategy. By providing these capabilities in-house, MSK removes barriers that typically slow the translation of discoveries into treatments.

The institutional model has attracted attention from the broader healthcare and business communities. MSK's approach was featured in Harvard Business Review under the headline "U.S. Medical Centers Need a New Model for Drug Discovery and Development," and in Nature Medicine with an article titled "Reinventing biotech systems for patient impact." These publications suggest that MSK's model may represent a template for how other academic medical centers could improve their innovation pipelines.

For industry partners, investors, and academic collaborators, the OEC operates with an explicit openness to partnerships. The office manages business development and licensing across both life sciences and digital health portfolios, recognizing that cancer innovation extends beyond traditional pharmaceuticals into software, diagnostics, and data analytics. In a healthcare environment defined by evolving regulatory requirements, economic pressures, and shifting global health needs, this flexibility positions MSK as a partner capable of adapting to emerging opportunities.

The broader significance of MSK's approach lies in its recognition that innovation infrastructure matters as much as scientific talent. Many academic institutions excel at discovery but struggle with commercialization, leaving potentially transformative treatments stuck in the lab. By building dedicated teams, funding mechanisms, and partnership networks, MSK demonstrates that the gap between "interesting research" and "patient benefit" is not inevitable. It is a gap that can be systematically addressed through institutional design and commitment to the full innovation lifecycle.